Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 63

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 63
---
TELO), or Telomir. MIRA and Telomir have the same executive officers and share a majority of the members of their respective board of directors. Furthermore, the Bay Shore Trust owns 5,406,431 shares of Telomir as well as the percentage holdings in each of MIRA and SKNY as are described above.

Structure

Under the Merger Agreement, Merger Sub, a wholly owned subsidiary of MIRA formed in connection with the Merger, will merge with and into SKNY, with SKNY surviving as a wholly owned subsidiary of MIRA. Following the Merger, MIRA expects to continue to trade on The Nasdaq Capital Market under the symbol “MIRA.”

Executive Officers of the Combined Company Following the Merger

Immediately following the Merger, the executive management team of the combined company is expected to remain the same as prior to the Merger, and be comprised of the following individuals with such additional officers as may be added by the combined company:

| Name         |     | Position          
 with MIRA         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 31 |

Directors of the Combined Company Following the Merger

Following the Merger, the combined company is expected to retain four of the current directors of MIRA as were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov; Edward MacPherson and Dr. Matthew Paul Del Giudice, and for the fifth director, Dr. Denil Nanji Shekhat, will be replaced by Kelly Stackpole, the current CEO of SKNY, with each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. The aforementioned board of directors will maintain its audit committee, compensation committee and nominating and corporate governance committee, in accordance with the Nasdaq rules.

Merger Consideration and Exchange Ratio

For a discussion of the merger consideration and the Exchange Ratio, please see the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.”

Accounting Treatment of Merger

MIRA will account for the transaction as an asset purchase under the guidance provided in ASC 805-10-55-5 through ASC 805-10-55-9. MIRA concluded that under the applicable rules, the Merger meets the criteria for an asset acquisition rather than a business combination. Neither MIRA nor